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OBJECTIVES: In 2011 was introduced the early benefit assessment with the new
pharmaceutical restructuring act (AMNOG) in Germany. Only new launched phar-
maceuticals were assessed since this date. At the beginning of June were the first
calls by FJC of drugs which made available for the market before 2011. The objection
is to show relevant criteria for calling a launched product and to analyze which
issues and consequences are possible in the AMNOG process. METHODS: In the
first step was described the political situation before and after the AMNOG and the
potential criteria for a call of launched drugs prior the law. Afterwards it was shown
the dossier development and assessment, hearing, G-BA decision and price nego-
tiation. There were demonstrated possible issues and differences between assess-
ments of new and launched products in this procedure. RESULTS: There is only a
small time frame for dossier development and assessment. Manufacturers and
concerned institutions have to plan and prepare in early expected time. Pharma-
ceuticals mostly admitted for more than one indication, why there could be a high
number of clinical trials available. The assessment of prior 2011 launched drugs is
very difficult, because there was a retrospective change of frame conditions. The
main criteria for a call are the market volume and revenues, remaining patent
protection and the expected assessments of competitors, triggered by admission of
new drugs in next time. CONCLUSIONS: In the next years can be expected, that
G-BA will be assess more pharmaceuticals from indications that have a great in-
fluence for costs in German health care. The methods and criteria have to be
discussed with all involved parties.
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OBJECTIVES:Health plans and other decision making bodies regularly request that
pharmaceutical and biotechnology companies provide a standardized dossier con-
taining detailed information - not only on the drug’s safety and efficacy, but also on
its overall clinical, economic, and humanistic value relative to alternative thera-
pies. Independent focus groups and multi-country surveys identified several chal-
lenges related to convenient, real-time collaboration to access information and
tools developed by the pharmaceutical and biotechnology industry METHODS: In
the US, the Academy of Managed Care Pharmacy (AMCP) partnered with Dy-
maxium Healthcare Innovations to launch an electronic platform to meet imme-
diate needs of US (Health Care Decision Makers (HCDMs). The platform would
incorporate all the key components of decision making processes, and was de-
signed with leading HCDMs. A survey was also fielded to over 50 US decision mak-
ers and payers from 13 other countries to provide their feedback and input into
their local HTA needs. Local country HTA guidelines and formats (i.e AMCP format
in the US) from over 30 countries was incorporated into the overall design of the
platform. RESULTS: The US HCDM survey results indicated the following chal-
lenges: a) Difficulty navigating through large volumes of information (300 pages)
to use for internal reviews, b) Risks associated with review of information that is
out-dated due to the release of newly published safety and effectiveness informa-
tion, c) Lack of user-friendly, transparent models and tools that can be customized
to reflect a plan’s own population patterns. The international survey revealed sim-
ilar challenges and unmet needs by HCDMs that were similar to their US counter-
parts. This feedback is being incorporated into the development of international
versions of the eDossier system. CONCLUSIONS: Leading experts from regional
countries validated the unique needs of each region in conducting HTA reviews
and the various benefits an electronic platform such as the AMCP eDossier may
provide.
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OBJECTIVES: The patient perspective is considered critical for policy decision mak-
ers. However it is unclear how this perspective is incorporated within different HTA
processes. The research identified and compared how selected European HTA
agencies incorporate the patient view in the decision making process for drugs.
METHODS:We identified websites of six relevant European bodies: England (NICE),
France (HAS), Germany (IQWIG and GBA), Scotland (SMC) and Sweden (TLV). We
searched for: how PAG representatives are selected, how they provide input &
contribute to the decision making process and how they are supported by HTA.
Findings were transferred to Excel spreadsheet and sent to respective agencies for
validation. Five of the six HTA responded. RESULTS: No weighting exists on how
Patient Advocacy Group (PAG) input is measured with respect to other data sub-
missions, important differences were observed in the engagement of PAGs as part
of the HTA assessment. HAS appears to have little or no process for PAG involve-
ment in HTA. NICE, SMC and GBA provide a support unit to facilitate PAG input. The
selection process of PAG for involvement in the process is well defined for G-BA,
TLV, NICE and SMC though TLV uses PAGs not related to the disease area under
review. G-BA & IQWIG involve individual patients, PAGs & consumer groups. Com-
prehensive PAG input to the process is publicly available for NICE and SMC. Only
TLV offers an equal voting right for PAGs. CONCLUSIONS: The patient perspective
is a significant contributor in the HTA decision making process. Although all HTA
agencies rely on patient information, significant differences exist in methods of
selection, input, impact and effort to support PAG input. Although such differences
are likely linked to cultural differences there is a need to improve and standardize
PAG input and integration in HTA decision making.
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OBJECTIVES: Personalized medicine is the use of diagnostic testing, including ge-
netic testing, to refine patient selection for the use of high cost procedures, devices,
and medicines. This study compares the processes for making coverage decisions
on multiple technologies between UK and Australia. METHODS: Comparative
study of assessments published by UK’s National Institute for Health and Clinical
Excellence (NICE) and Australia’s Commonwealth Department of Health.RESULTS:
The coverage of medical procedures, devices, and pharmaceuticals has been as-
sessed separately by different committees using conventional approaches of eco-
nomic evaluation in both UK and Australia. In 2005, NICE introduced a process to
assess multiple technologies (medicines, devices, medical procedures), such as
several drugs for the same condition, or one drug for several conditions. By con-
trast, Australia recently introduced an integrated assessment specifically for mul-
tiple, co-dependent technologies (‘personalized medicine’ products), such as med-
icines and their companion diagnostic tests. Health technologies are co-dependent
if their use needs to be combined to achieve or enhance the intended clinical effect
of either technology (e.g. gefitinib for patients with tested positive for an activating
mutation of the epidermal growth factor receptor gene in tumor). The co-depen-
dent technology assessment process was established in response to concerns that
1) only one technology in the co-dependent is reimbursed (e.g. a medicine is cov-
ered by the drug formulary while the companion test to determine responders is
not covered by Medicare), and 2) the assessment of a co-dependent technology
should consider the benefits and costs of their joint use, as distinct to the benefits
and costs of each technology alone. Analysis is underway to compare the timeli-
ness and recommendationsfor personalized medicine products between UK and
Australia. CONCLUSIONS: Important lessons are to be learned from the existing
experiences as health technologies are increasingly used either sequentially or
simultaneously in the continued development of personalized medicine.
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OBJECTIVES: The AMNOG has been in place for new drugs in Germany since 01/
01/2011. The AMNOG includes early benefit assessment in comparison to one pre-
defined ‘appropriate comparator’ therapy and negotiation of reimbursement price.
The objective of this research was to review and compare the outcomes of all
benefit assessments which had had in place a final decision until June 2012.
METHODS: A review based on all published documents of the AMNOG processes
(benefit dossiers submitted, IQWiG assessment reports and final G-BA decisions).
This investigation focuses on the comprehensive description and comparison of
outcomes of assessment and final decision. RESULTS: Until June 10, 2012, a total of
n14 AMNOG processes were finalized. For further 4 processes no dossier was
submitted. An additional benefit was partially credited 7 (50 %) out of the 14 new
drugs by the IQWiG and 10 (71%) by the G-BA. The IQWiG differentiated 39 sub-
populations for separate assessment and the G-BA considered 31 subpopulations
in the final decisions. The IQWiG credited 26 out of 39 subpopulations (67 %) with
‘no proof of additional benefit’. A total of 3 (8 %) subpopulations was credited with
‘significant’ additional benefit, 2 (5%) with ‘marginal’, and 6 (16 %) with ‘additional
benefit not quantifiable’. The G-BA finally credited 18 out of 31 subpopulations
(58%) with ‘no proof of additional benefit’ or ‘less benefit’. A total of 2 (6%) subpopu-
lations were credited with ‘significant additional benefit’, 5 (16%) with ‘marginal
additional benefit’, and 6 (20%) with ‘additional benefit not quantifiable’.
CONCLUSIONS: The AMNOG evaluation of additional benefit differentiates a high
number of subpopulations. Obviously the number of subpopulations and the out-
comes varied between IQWiG assessment and final G-BA decision. So far, the ma-
jority of subpopulations were credited with ‘no proof of additional benefit’. First
results from reimbursement negotiations suggest that this may restrict price
agreement.
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OBJECTIVES: The Act on the Reform of the Market for Medicinal Products (AMNOG)
funds, effective since 01.01.2011, implemented an early benefit assessment of
drugs after launch in Germany. The Institute for Quality and Efficiency in Health
Care (IQWiG) assesses the benefit of a drug based on a dossier submitted by the
pharmaceutical manufacturer. Based on this assessment and the statements by
industry, scientific community and patient organizations the Federal Joint Com-
mittee (FJC) reviews and decides on the extent of the additional benefit being the
basis for price negotiations between the National Association of Statutory Health
Insurance Funds and the pharmaceutical manufacturer. The objective is to inves-
tigate possible differences between the scientific assessments by IQWiG and the
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